Eli Lilly Reports POC Data of LY-CoV555 in P-II BLAZE-1 Study for COVID-19 in Outpatient Setting

 Eli Lilly Reports POC Data of LY-CoV555 in P-II BLAZE-1 Study for COVID-19 in Outpatient Setting

Eli Lilly Reports POC Data of LY-CoV555 in P-II BLAZE-1 Study for COVID-19 in Outpatient Setting

Shots:

  • The P-II BLAZE-1 study involves assessing of LY-CoV555 and LY-CoV01 for symptomatic COVID-19 in the outpatient setting. The trial enrolled mild-to-moderate recently diagnosed COVID-19 patients across four groups i.e. LY-CoV555 (700mg/2800mg/7000 mg) vs PBO
  • The 1EPs i.e. change from baseline in viral load @11days was met with 2800mg dose level, but not the others. LY-CoV555 showed a positive impact on COVID-19-related hospitalization or ER visit (1.7% vs 6%) relating to a 72% risk reduction in this limited population, no patients progressed to mechanical ventilation or died, rate of resistance variants (8% vs 6%)
  • LY-CoV555 is a potent, neutralizing IgG1 mAb targeting the spike protein of SARS-CoV-2 and is well tolerated with no AEs. The BLAZE-1 study is ongoing with additional treatment arms

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: WFYI

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post